Referring to recent company's announcement:"ANP is...

Referring to recent company's announcement:

"ANP is presentlywithholding details on the new disease indications to allow for additional patent protection for the use of ATL1102 in these indications to be filed upon experimental success. Where applicable ANP would also look to seek Orphan Drug designation for additional market protection.

The Company has continued to file new patent applications to protect the use of ATL1102 in new immune-mediated inflammatory muscle indications with the submission last year of International patent application PCT/AU2020/050445 to be progressed with patent applications in the National
phase.

As previously advised, the broader immunomodulatory effects of ATL1102 are being investigated by ANP through the analysis of blood (plasma) samples retained from the Company’s Phase II trial of ATL1102 in DMD patients. ANP is presently completing this plasma analysis and is expecting this new
data to provide insights on the mode of action and broader biological activity of ATL1102. ANP is planning to file for additional patent protection with this new data ahead of its proposed presentation at an appropriate scientific conference in 2H’CY21. "

Be patient, we'll expecting more new indications and possible NEW Orphan Drug Designation.....as advised by ANP,--> with this new data ahead of its proposed presentation at an appropriate scientific conference in 2H’CY21. "... most probably by October - November 2021